Tagged Articles

Bayer 143 articles

More patients being treated for atrial fibrillation


More patients than ever are being treated with blood thinners for the common irregular heart rhythm condition atrial fibrillation, thanks in part to direct-to-consumer advertising from the newest anticoagulants on the market. According to a study conducted by researchers with the University of Michigan Frankel Cardiovascular Center, doctors prescribed more than 2.83 million blood thinners in the last quarter of 2014, up about 800,000 from the start of 2009. Blood thinners are used to prevent strokes in patients with atrial fibrillation. They are also used to prevent or treat blood clots in the legs and lungs, a condition known as ... Read More

Elderly patients taking Xarelto at greater risk of major bleeds


Elderly patients with a common irregular heart rhythm known as atrial fibrillation treated with the blood thinner Xarelto are far more likely than any other age group to experience major bleeding events, according to a post-marketing study investigating the safety risks with the popular new anticoagulant. The multi-year study involved medical records of 31,883 atrial fibrillation patients ages 19 to 105 prescribed Xarelto for stroke prevention. Researchers used a validated case-finding algorithm to detect major bleeds, which matched diagnosis codes related to bleeding with patient identities. Patient demographics were identified, as was usage of other medications, treatment for bleeding, and ... Read More

Mirena IUD side effects Facebook post goes viral

mirena IUD

Samantha Yoakum was shocked to find that her Facebook post warning of the dangers of the Mirena IUD went viral. She wrote the original post on July 6, and within days it spread through social media. Women were shocked. The Mirena IUD, made by Bayer, is a flexible T-shaped contraceptive device that is inserted into the cervix to prevent pregnancy and, in some cases, reduce heavy menstrual bleeding for up to five years. It has been linked to serious side effects and several lawsuits have been filed against Bayer by women who claim they have been injured by the devices. ... Read More

New class of blood thinners linked to serious bleeding risks


Makers of the novel new anticoagulants Pradaxa, Xarelto and Eliquis have shelled out a lot of money to advertise their blood thinners directly to consumers, but what may not be as obvious is how much these drug companies are paying doctors to tout the benefits of their drugs. According to Pro Publica, which reports an analysis of Sunshine Act data, Pfizer and Bristol-Myers paid $8 million to doctors to talk up Eliquis during the last five months of 2013. Bayer and Johnson & Johnson reportedly paid $6.93 million to doctors to promote Xarelto, and Boehringer Ingelheim gave $4.43 million to ... Read More

Xarelto lawsuits mount in recent months


Lawsuits involving the bleeding side effects with the blood thinner Xarelto have seen a steady increase in recent months according to an analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation through mid-June. The biggest increases in new filings were seen in products liability litigation before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. The lawsuits target Xarelto makers Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals. The lawsuits allege the drug makers did not adequately warn of major bleeding events including gastrointestinal bleeds and brain hemorrhages associated with use of the drug. Xarelto is ... Read More

Antidote in development for blood thinner Pradaxa


Drugmaker Boehringer Ingelheim announced that early data on its experimental drug idarucizumab has shown that it effectively reverses the effects of the company’s blood thinner Pradaxa in a late-stage study. Pradaxa was the first drug in a new line of anticoagulants designed to replace the long-used warfarin for the prevention of blood clots in patients with the common heart rhythm abnormality known as atrial fibrillation. The drug hit blockbuster status quickly, but sales slowed when reports of major bleeding events began to mount. Unlike warfarin, there is no antidote to revers the blood thinning effects of Pradaxa. Pradaxa’s entrée to ... Read More

Judge upholds whistleblower claims against Bayer over off-label Trasylol marketing


Two whistleblower claims accusing Bayer of promoting its heart surgery drug Trasylol for unapproved purposes will move forward after a New Jersey federal judge on Monday again declined the drug maker’s motion to dismiss the case. In March, U.S. District Judge Jose Linares refused Bayer’s motion to drop the False Claims Act case. Bayer asked Judge Linares to reconsider the March order, arguing that the court missed its arguments that whistleblower Laurie Simpson failed to demonstrate how its alleged wrongful marketing of Trasylol amounted to a submission of false claims to the government. Bayer also argued the court overlooked its ... Read More

Bleeding side effects, lawsuits may hurt future Xarelto sales


Sales of Pfizer’s new blood thinner Eliquis have grown more than fivefold in the previous year to a whopping $774 million, but analysts say Johnson & Johnson and Bayer need not fret just yet about the fate of their blockbuster blood thinner Xarelto. Xarelto has the lion’s share of the anticoagulant market of the new lineup of blood thinners known as Xa inhibitors. Boehringer Ingelheim’s Pradaxa, which hit the market in 2010, was the first in the class of drugs designed to go head-to-head with the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. Pradaxa revenues grew ... Read More

Xarelto, GranuFlo and NaturaLyte lawsuit filings increase in April

Fresenius sign

The largest increases in product liability filings involving pharmaceuticals last month were seen in claims against Bayer and Janssen Pharmaceuticals’ blood thinner Xarelto, and Fresenius Medical Care’s dialysis concentrates GranuFlo and NaturaLyte, according to Reuters’ analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation. Bayer and Janssen, a subsidiary of Johnson & Johnson, have enjoyed billion-dollar profits from their blood thinner Xarelto since it hit the market in 2011. Xarelto has since been approved for multiple indications including stroke prevention in patients with nonvalvular atrial fibrillation, treating and preventing blood clots in the legs and lungs, and preventing blood ... Read More

Xarelto makers not worried about blood thinner’s competition


It’s a dog-eat-dog world out there, especially in the pharmaceutical industry. And no one wants to admit when the chips are down. But drug company Bayer is totally blowing off concerns that its blockbuster blood thinner Xarelto may be losing market share in the United States to Bristol-Myers Squibb’s Eliquis. Xarelto and Eliquis are blood thinners that are used to prevent strokes and blood clots in patients with a heart condition known as atrial fibrillation, prevent and treat blood clots in the legs and lungs, and prevent blood clots in patients undergoing knee or hip replacement therapy. The drugs are ... Read More